Dr. J.J. Kiladjian at ASH 2017, Ropeginterferon Induces High Rates of Clinical, Hematological and Molecular Responses in PV Patients
Two Year Results from the First Prospective Randomized Controlled Trial -
Hope you find the interview informative.
David Wallace - PV Reporter
It does seem that interferon is becoming the stronger option.
It would be my first choice, but all patients are different. This option should be discussed with your hematologist to weigh the pros and cons.
Start a Community